Financial Performance - The net profit attributable to shareholders for 2024 is CNY 163,061,272.77, with the parent company achieving a net profit of CNY 112,390,863.64[6]. - The proposed cash dividend is CNY 2.20 per 10 shares, totaling CNY 49,078,996.34, which represents 30.10% of the annual net profit attributable to shareholders[6]. - The total distributable profit at the end of the year is CNY 478,883,838.60 after accounting for the cash dividend distribution and the statutory surplus reserve[6]. - The company's operating revenue for 2024 reached ¥1,915,159,154.27, representing a year-on-year increase of 5.26% compared to ¥1,819,516,165.79 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥163,061,272.77, showing a significant increase of 82.65% from ¥89,275,234.00 in 2023[24]. - The basic earnings per share for 2024 increased to ¥0.73, up 82.50% from ¥0.40 in 2023[25]. - The weighted average return on equity rose to 15.06%, an increase of 6.05 percentage points compared to 9.01% in 2023[25]. - The net assets attributable to shareholders at the end of 2024 were ¥1,135,611,595.12, reflecting a 13.40% increase from ¥1,001,446,115.48 at the end of 2023[24]. - The total assets at the end of 2024 amounted to ¥1,980,057,333.84, which is a 6.27% increase from ¥1,863,168,849.07 at the end of 2023[24]. - The cash flow from operating activities for 2024 was ¥49,027,345.54, a decrease of 16.18% compared to ¥58,492,291.10 in 2023[24]. Corporate Governance - The company has a commitment to ensuring the accuracy and completeness of the annual report, with all board members present at the meeting[3][4]. - The audit report issued by the accounting firm is a standard unqualified opinion, confirming the financial report's integrity[5]. - The company has established a robust internal control system to enhance operational management and risk prevention capabilities[133]. - The company has ensured the independence of its operations, assets, finances, personnel, and institutions following the transfer of shares to Baillan Group, which became the controlling shareholder[135]. - Baillan Group has committed to maintaining the operational independence of the company, ensuring it has independent procurement, production, and sales capabilities[136]. - The company guarantees that its assets, including operating licenses, intellectual property, and related facilities, are fully owned or used independently by the company[137]. - The financial independence of the company is assured, with a separate accounting department and financial personnel not involved in Baillan Group's other entities[137]. - The company has established a complete and independent corporate governance structure, ensuring no institutional overlap with Baillan Group[138]. - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[126]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with legal and regulatory requirements[128]. Market and Operational Strategy - The company plans to enhance its core competitiveness and support high-quality development as part of its strategic goals for the "14th Five-Year Plan" period[32]. - The company is focusing on improving front-end business operations and strengthening backend support to drive growth[32]. - The company expanded its retail network, reaching a total of 206 stores with a net increase of 35 stores during the reporting period, including 2 new pet specialty stores[33]. - The company added 53 medical insurance stores, with medical insurance stores accounting for over 60% of the total, surpassing the average coverage rate in the Shanghai market[33]. - Online business continued to grow, with the company ranking among the top 4 in O2O sales in Shanghai, showing significant improvement compared to previous years[37]. - The company launched 28 new products through strategic partnerships, enhancing collaboration with suppliers to promote sustainable business growth[38]. - The company established a traditional Chinese medicine decoction service center, becoming one of the first wholesale enterprises to meet group standards, aimed at improving patient service[37]. - The company aims to complete the construction of a modern intelligent logistics center by 2025, which will improve logistics efficiency and reduce costs[39]. - The company is adapting to the "Internet + healthcare" trend by collaborating with major platforms like JD.com and Tmall to meet the growing online medication purchasing demand[56]. - The company aims to improve its operational efficiency by adjusting its product structure in response to new pricing regulations from the National Medical Insurance Administration[49]. Community Engagement and Social Responsibility - The company conducted over 1,400 community health activities, reaching nearly 50,000 people, enhancing brand influence in local communities[35]. - The company has committed 27.18 million yuan to poverty alleviation efforts, benefiting 1,292 individuals through consumption assistance[191]. - The company made a total donation of 2.5 million yuan, including 2.5 million yuan in material donations for disposable masks to support 2,948 individuals in need[187]. - The company has implemented a comprehensive quality management training program to meet industry standards[173]. - The company emphasizes the importance of continuous and stable profit distribution while ensuring sustainable development[165]. Challenges and Risks - The company faces challenges from price reductions due to centralized procurement and increased competition from online platforms like JD and Alibaba[114]. - The company faces risks from industry policy changes, including the impact of "two-invoice system" and "volume-based procurement," which may increase cost pressures on pharmaceutical retail operations[120]. - Market competition is intensifying, with challenges from online medical services and changing consumer behaviors, necessitating adaptation to maintain competitiveness[120]. - Financial risks are present due to potential short-term increases in investment and expenses outpacing revenue growth during business transformation efforts[121]. Employee Development and Management - The company has implemented a flexible compensation policy based on "distribution according to work" and "efficiency first while considering fairness" to attract and retain talent[160]. - In 2024, the company will focus on training and talent development as a key measure to enhance competitiveness and employee quality[162]. - The company plans to strengthen the selection and training of young cadres and improve the talent selection mechanism[162]. - A new online training platform and internal/external course resources will be developed to meet talent development and reserve requirements[162]. - The company aims to cultivate a team of self-driven and agile future stars through its "New Talent Program" and "Little Cow" talent cultivation plan[162]. Financial Management and Audit - The company has established a mechanism for profit distribution decision-making that includes independent directors' opinions[169]. - The internal control audit report received a standard unqualified opinion, indicating effective internal control practices[181]. - The company has not faced any environmental penalties and adheres to national environmental protection laws and regulations[184]. - The company has not taken any carbon reduction measures during the reporting period, resulting in zero reduction in carbon emissions[185]. - The company has maintained good management control over its subsidiaries, with no loss of control reported[182].

证券代码：600833 证券简称：第一医药 公告编号：2025-010 | 1、出席会议的股东和代理人人数 | 277 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 113,501,285 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 50.8777 | 上海第一医药股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 表决，符合《公司法》等有关法律、法规及《公司章程》的有关规定。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 由公司董事长张海波先生主持。会议采用现场投票及网络投票相结合的方式 (一) 股东大会召开的时间：2025 年 2 月 27 日 (二) 股东大会召开的地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持 ...

上海市金茂律师事务所 关于上海第一医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：上海第一医药股份有限公司 （引言） 上海第一医药股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会（以下简称"本次股东大会"）于 2025 年 2 月 27 日在上海市徐汇区小木 桥路 681 号 20 楼第三会议室召开。上海市金茂律师事务所经公司聘请委派韩春 燕律师、路遥律师（以下简称"本所律师"）出席会议，就本次股东大会的召集、 召开程序，出席会议人员资格，会议议案，以及会议的表决程序、表决结果等发 表法律意见。 本法律意见书根据《中华人民共和国公司法（2023 修订）》（以下简称"《公 司法》"）、《中华人民共和国证券法（2019 修订）》（以下简称"《证券法》"）、 《上市公司股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作（2023 年 12 月 修订）》（以下简称"《自律监管指引 1 号》"）等有关法律、法规和规范性文 件以及《上海第一医药股份有限公司章程》（以下简称"《公司章程》"）而出 具。 为出具本 ...

上海第一医药股份有限公司 2025 年第一次临时股东大会 会议资料 二○二五年二月二十七日 上海第一医药股份有限公司 2025 年第一次临时股东大会 会议资料 会议资料目录 | 一、2025 | 年第一次临时股东大会会议议程 ………………………… | 1 | | --- | --- | --- | | 二、2025 | 年第一次临时股东大会会议须知 ………………………… | 2 | | 三、关于 2025 | 年度为全资子公司提供担保额度预计的议案 ………4 | | | 四、关于公司拟签订房屋征收补偿协议的议案……………………7 | | | | 五、关于 2025 | 年度日常经营性关联交易预计的议案………………8 | | 上海第一医药股份有限公司 2025 年第一次临时股东大会 会议资料 上海第一医药股份有限公司 2025 年第一次临时股东大会会议议程 会议时间： 现场会议时间：2025 年 2 月 27 日（星期四）下午 13:30 网络投票起止时间：自 2025 年 2 月 27 日 至 2025 年 2 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的 投票时间为股东大会召开当日的 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-008 上海第一医药股份有限公司 甲方：上海市黄浦区住房保障和房屋管理局；房屋征收实施单位：上海市黄浦第五 房屋征收服务事务所有限公司 乙方：上海第一医药股份有限公司 关于公司拟签订房屋征收补偿协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、本次交易概述 根据上海市黄浦区人民政府《上海市黄浦区人民政府房屋征收决定》（黄府征【2023】 4 号），上海第一医药股份有限公司（以下简称"我司""公司"）位于上海市黄浦区 四川中路 553-555 号、四川中路 545 号、四川中路 639 号三处房屋被纳入征收范围。上 述三处房屋由我司经营管理，曾主要用于对外出租经营使用。本次房屋征收单位为"上 海市黄浦区住房保障和房屋管理局"，房屋征收实施单位为"上海市黄浦第五房屋征收 服务事务所有限公司"，房屋评估单位为"上海房地产估价师事务所有限公司"。 经多次协商，目前已就征收补偿事宜基本达成一致，我司拟与房屋征收单位、房屋 征收实施单位签订《上海市国有土地 ...

证券代码：600833 证券简称：第一医药 公告编号：2025-007 上海第一医药股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2025 年第一次临时股东大会 召开的日期时间：2025 年 2 月 27 日 13 点 30 分 召开地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 至 2025 年 2 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七) ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-005 上海第一医药股份有限公司 第十届监事会第十六次（临时）会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、公司《关于 2025 年度日常经营性关联交易预计的议案》 重要内容提示：本次监事会不存在否决议案，没有监事投反对/弃权票。 上海第一医药股份有限公司第十届监事会第十六次（临时）会议于 2025 年 2 月 6 日以邮件方式通知，于 2025 年 2 月 11 日以通讯方式召开。本次会议由监事长李峰召集 并主持，本次会议应参加表决监事 3 名，委托 0 名，实际参加表决监事 3 名。会议的召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。根据会议 议程，本次会议审议通过了以下事项： 1 二、备查文件 公司第十届监事会第十六次（临时）会议决议 特此公告。 上海第一医药股份有限公司监事会 2025 年 2 月 12 日 具体内容详见上海证券交易所网站 http://www.sse.com.cn 公司《关于 2025 年 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-004 上海第一医药股份有限公司 第十届董事会第三十次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 具体内容详见同日公告于上海证券交易所网站（http://www.sse.com.cn）的《关 于召开 2025 年第一次临时股东大会的通知》（公告编号：临 2025-007）。 表决结果：赞成 9 名，反对 0 名，弃权 0 名 上海第一医药股份有限公司（以下简称"公司"）第十届董事会第三十次（临时） 会议于 2025 年 2 月 6 日以邮件方式通知，于 2025 年 2 月 11 日以通讯方式召开。本次 会议由董事长张海波先生召集并主持。本次会议应参加表决董事为 9 名，委托表决 0 名， 实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公 ...